These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 17257447)

  • 21. Dose conversion ratio one year after switching from epoetin alpha to darbepoetin alpha in Japanese hemodialysis patients.
    Hirai T; Nakashima A; Shiraki N; Takasugi N; Yorioka N
    Int J Artif Organs; 2010 May; 33(5):283-9. PubMed ID: 20593349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
    Herrington JD; Davidson SL; Tomita DK; Green L; Smith RE; Boccia RV
    Am J Health Syst Pharm; 2005 Jan; 62(1):54-62. PubMed ID: 15658073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials?
    Roger SD; Cooper B
    Nephrology (Carlton); 2004 Aug; 9(4):223-8. PubMed ID: 15363054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
    Schwartzberg LS; Yee LK; Senecal FM; Charu V; Tomita D; Wallace J; Rossi G
    Oncologist; 2004; 9(6):696-707. PubMed ID: 15561813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Darbepoetin alfa: new indication/new dosage. No proven advantage in chemotherapy-induced anaemia.
    Prescrire Int; 2005 Oct; 14(79):174-6. PubMed ID: 16285072
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
    Molina M; García Hernández MA; Navarro MJ; Pérez Silva F; Cacho M; De Gracia MC
    Nefrologia; 2004; 24(1):54-9. PubMed ID: 15083958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature.
    Ross SD; Allen IE; Henry DH; Seaman C; Sercus B; Goodnough LT
    Clin Ther; 2006 Jun; 28(6):801-31. PubMed ID: 16860166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ; Jacobson DR
    Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
    Song X; Long SR; Marder WD; Sullivan SD; Kallich J
    Ann Pharmacother; 2009 Jul; 43(7):1203-10. PubMed ID: 19584392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
    Case AS; Rocconi RP; Kilgore LC; Barnes MN
    Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dosing patterns, drug costs, and hematologic outcome in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa.
    Hymes J; Bickimer T; Jackson JH; Bookhart BK; Mody SH; Tak Piech C
    Curr Med Res Opin; 2007 Aug; 23(8):1931-7. PubMed ID: 17624232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.
    Nurko S; Spirko R; Law A; Dennis VW
    Clin Ther; 2007 Sep; 29(9):2010-21. PubMed ID: 18035200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Budget impact analysis of darbepoetin alfa every 3 weeks versus epoetin alfa every week for the treatment of chemotherapy-induced anaemia from a US payer's perspective.
    Rubin RJ; Glaspy JA; Adams JL; Mafilios MS; Wang SM; Viswanathan HN; Kallich JD
    J Med Econ; 2008; 11(2):199-213. PubMed ID: 19450080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epoetin alfa and darbepoetin alfa for the treatment of chemotherapy-related anemia in cancer patients in Sweden: comparative analysis of drug utilization, costs, and hematologic response.
    Persson U; Borg S; Jansson S; Ekman T; Franksson L; Friesland S; Larsson AM
    Adv Ther; 2005; 22(3):208-24. PubMed ID: 16236682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomised, cross-over study comparing injection site pain with subcutaneous epoetin beta and subcutaneous darbepoetin alfa in patients with chronic kidney disease.
    Roger SD; Suranyi MG; Walker RG; Disney A; Isbel NM; Kairaitis L; Pollock CA; Brown FG; Chow J; Truman MI; Ulyate KA;
    Curr Med Res Opin; 2008 Aug; 24(8):2181-7. PubMed ID: 18565240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comment on: The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease.
    Einarson T; Machado M; Walker J; Iskedjian M
    Curr Med Res Opin; 2007 Jul; 23(7):1571-3; author reply 1573-4. PubMed ID: 17637205
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinical and economic comparison of epoetin alfa and darbepoetin alfa.
    Morreale A; Plowman B; DeLattre M; Boggie D; Schaefer M
    Curr Med Res Opin; 2004 Mar; 20(3):381-95. PubMed ID: 15025847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
    Winkelmayer WC; Chang TI; Mitani AA; Wilhelm-Leen ER; Ding V; Chertow GM; Brookhart MA; Goldstein BA
    Am J Kidney Dis; 2015 Jul; 66(1):106-13. PubMed ID: 25943715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical outcomes associated with conversion from epoetin alfa to darbepoetin alfa in hospitalized hemodialysis patients.
    Sarac E; Chikyarappa A; Sabol B; Gemmel D; Globe D; Barlev A; Audhya P
    Am J Nephrol; 2006; 26(6):571-8. PubMed ID: 17170523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome.
    Patton JF; Sullivan T; Mun Y; Reeves T; Rossi G; Wallace JF
    J Support Oncol; 2005; 3(6):419-26. PubMed ID: 16350429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.